Tenaya Therapeuticsの空売り状況は、投資家がTenaya Therapeuticsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Tenaya Therapeutics (NASDAQ:TNYA) 株価情報, 空売り情報

TENAYA THERAPEUTICS INC

Tenaya Therapeutics

Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.

Tenaya Therapeutics Inc

WIIM

AMAT

INDI

KLAC

LRCX

MCHP

NVDA

SMCI

TSEM

Shares of chip stocks are trading higher amid overall market volatility. Stocks across sectors have been volatile on Monday, with tech stocks rebounding following earlier weakness.

Trading Ideas

ZBAO

Zhibao Technology Shares Resumed Trade

UBS analyst Steven Fisher downgrades Martin Marietta Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLM#NYSE">MLM</a>) from Buy to Neutral and announces $491 price target.

News

Downgrades

Price Target

Analyst Ratings

UBS Downgrades Martin Marietta Materials to Neutral, Announces $491 Price Target

The market just slipped through what JPMorgan&#8217;s Jason Hunter calls a "fork in the road" — only this time, it&#8217;s more like tumbling through a black hole. Hunter says the recent U.S. trade policy surprise pushed <a href="https://www.benzinga.com/topic/s-p-500">the S&amp;P 500</a> index below a critical level near 5500, triggering what could be an accelerated pricing of recession risks.
<h1 class="wp-block-heading">Key Support Breached – Now What?</h1>
Hunter highlights that the S&amp;P 500 didn't just tiptoe past support — it gapped straight through 5500, dipped through the mid-5300s and now hovers near a major support zone in the low 5100s.
He believes a bounce is possible from here, but don't bet the house on it. "We suspect the market can stage a bear market rebound&#8230; but believe that lift will be contained and potentially short-lived unless the news flow sees a dramatic change," he warns.
Read Also: <a href="https://www.benzinga.com/markets/equities/25/04/44660697/how-to-protect-against-a-1987-style-s-p-500-crash-scenario">How to Protect Against A 1987-Style S&amp;P 500 Crash Scenario</a>
<h1 class="wp-block-heading">The Yield Curve Has Its Own Drama</h1>
In the bond world, the 2-year Treasury note flirted with resistance at 3.48%-3.55% before backing off. Hunter now sees a ceiling at 3.825%-3.85%, but expects an eventual bullish breakout — translation: yields may start rising again soon.
<h1 class="wp-block-heading">How To Play It</h1>
For those looking to trade this technical twist, ETFs like the SPDR S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), which tracks the S&amp;P 500, or the ProShares UltraShort S&amp;P500 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SDS#NYSE">SDS</a>), leveraged inverse ETF for the S&amp;P 500, offer exposure. If you're watching yields, the iShares 1-3 Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHY#NASDAQ">SHY</a>), a 1–3 Year Treasury ETF, or the iShares 3-7 Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IEI#NASDAQ">IEI</a>), a 3–7 Year Treasury ETF, could be in focus.
The bottom line? 
The S&amp;P 500 just slipped past a critical technical threshold, and while a short bounce may lure some in, Hunter's charts are flashing caution. Don&#8217;t mistake this for a reset — it&#8217;s more likely the eye of the storm.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/econ-s/25/04/44669291/sp-500-officially-sinks-into-bear-market-heres-what-investors-need-to-know">S&amp;P 500 Officially Sinks Into Bear Market: Here&#8217;s What Investors Need To Know</a></li>
</ul>
Photo: Shutterstock

Broad U.S. Equity ETFs

Technicals

ETFs

iShares Trust Barclays 1-3 Year Treasury Bond Fund

S&P 500 Slips Through The Cracks, Analyst Spots Short-Lived Bounce Before Gravity Kicks In

Zhibao Technology Shares Resume Trade

In the preceding three months, 19 analysts have released ratings for First Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>), presenting a wide array of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">9</td>
<td align="right">9</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">4</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $259.32, a high estimate of $335.00, and a low estimate of $209.00. Highlighting a 8.01% decrease, the current average has fallen from the previous average price target of $281.89. 
<img src="https://www.benzinga.com/files/images/story/2025/1744048873_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The perception of First Solar by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;---------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Joseph Osha &#x7C;Guggenheim &#x7C;Lowers &#x7C;Buy &#x7C; $253.00&#x7C;$304.00 &#x7C; 
&#x7C;Jordan Levy &#x7C;Truist Securities &#x7C;Lowers &#x7C;Buy &#x7C; $245.00&#x7C;$285.00 &#x7C; 
&#x7C;Christine Cho &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $236.00&#x7C;$273.00 &#x7C; 
&#x7C;Joseph Osha &#x7C;Guggenheim &#x7C;Lowers &#x7C;Buy &#x7C; $304.00&#x7C;$335.00 &#x7C; 
&#x7C;Andrew Percoco &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Overweight &#x7C; $238.00&#x7C;$297.00 &#x7C; 
&#x7C;Jon Windham &#x7C;UBS &#x7C;Lowers &#x7C;Buy &#x7C; $285.00&#x7C;$360.00 &#x7C; 
&#x7C;Kashy Harrison &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Overweight &#x7C; $230.00&#x7C;$250.00 &#x7C; 
&#x7C;Philip Shen &#x7C;Roth MKM &#x7C;Maintains &#x7C;Buy &#x7C; $280.00&#x7C;$280.00 &#x7C; 
&#x7C;Christopher Dendrinos&#x7C;RBC Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $251.00&#x7C;$280.00 &#x7C; 
&#x7C;Mark Strouse &#x7C;JP Morgan &#x7C;Lowers &#x7C;Overweight &#x7C; $268.00&#x7C;$282.00 &#x7C; 
&#x7C;Ameet Thakkar &#x7C;BMO Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $230.00&#x7C;$260.00 &#x7C; 
&#x7C;Jordan Levy &#x7C;Truist Securities &#x7C;Lowers &#x7C;Buy &#x7C; $285.00&#x7C;$300.00 &#x7C; 
&#x7C;Vikram Bagri &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $236.00&#x7C;$254.00 &#x7C; 
&#x7C;Maheep Mandloi &#x7C;Mizuho &#x7C;Raises &#x7C;Outperform &#x7C; $259.00&#x7C;$218.00 &#x7C; 
&#x7C;Julien Dumoulin-Smith&#x7C;B of A Securities &#x7C;Lowers &#x7C;Buy &#x7C; $236.00&#x7C;$246.00 &#x7C; 
&#x7C;Christine Cho &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $273.00&#x7C;$275.00 &#x7C; 
&#x7C;Joseph Osha &#x7C;Guggenheim &#x7C;Maintains &#x7C;Buy &#x7C; $335.00&#x7C;$335.00 &#x7C; 
&#x7C;Tom Curran &#x7C;Seaport Global &#x7C;Announces &#x7C;Buy &#x7C; $274.00&#x7C;- &#x7C; 
&#x7C;Michael Blum &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $209.00&#x7C;$240.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to First Solar. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of First Solar compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of First Solar's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into First Solar's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/FSLR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on First Solar analyst ratings.</a>
<h2>Discovering First Solar: A Closer Look</h2>
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and India.
<h3>First Solar's Financial Performance</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: First Solar's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 30.68%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: First Solar's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 25.96%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): First Solar's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 5.05%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 3.34%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: First Solar's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.09.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FSLR

First Solar Stock: A Deep Dive Into Analyst Perspectives (19 Ratings)

In the last three months, 6 analysts have published ratings on Navitas Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>), offering a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $4.08, along with a high estimate of $5.00 and a low estimate of $1.50. A negative shift in sentiment is evident as analysts have decreased the average price target by 6.21%. 
<img src="https://www.benzinga.com/files/images/story/2025/1744048862_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A comprehensive examination of how financial experts perceive Navitas Semiconductor is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Joseph Moore &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Underweight &#x7C; $1.50&#x7C;$2.10 &#x7C; 
&#x7C;Kevin Cassidy &#x7C;Rosenblatt &#x7C;Maintains &#x7C;Buy &#x7C; $5.00&#x7C;$5.00 &#x7C; 
&#x7C;Tristan Gerra &#x7C;Baird &#x7C;Lowers &#x7C;Outperform &#x7C; $4.00&#x7C;$5.00 &#x7C; 
&#x7C;Kevin Cassidy &#x7C;Rosenblatt &#x7C;Maintains &#x7C;Buy &#x7C; $5.00&#x7C;$5.00 &#x7C; 
&#x7C;Quinn Bolton &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $4.00&#x7C;$4.00 &#x7C; 
&#x7C;Kevin Cassidy &#x7C;Rosenblatt &#x7C;Maintains &#x7C;Buy &#x7C; $5.00&#x7C;$5.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Navitas Semiconductor. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Navitas Semiconductor compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Navitas Semiconductor's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Navitas Semiconductor's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NVTS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Navitas Semiconductor analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into Navitas Semiconductor's Background</h2>
Navitas Semiconductor Corp develops ultra-efficient gallium nitride (GaN) semiconductors that are revolutionizing power electronics. GaN power ICs integrate GaN power with drive, control, and protection to enable fast charging, high power density, and energy savings for mobile, consumer, enterprise, eMobility, and new energy markets. The company operates as one reportable segment, the design, development, manufacture, and marketing of integrated circuits and related components for use in mobile device and other markets. Geographically, the company operates in China, Europe, United States, Rest of Asia and Others. The majority of revenue is generated from China.
<h3>A Deep Dive into Navitas Semiconductor's Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Navitas Semiconductor's revenue growth over a period of 3M has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -31.01%. This indicates a decrease in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -221.72%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Navitas Semiconductor's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -10.94%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Navitas Semiconductor's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -9.85%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Navitas Semiconductor's debt-to-equity ratio is below the industry average. With a ratio of 0.02, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NVTS

Forecasting The Future: 6 Analyst Projections For Navitas Semiconductor

In the current session, Monolithic Power Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>) is trading at $463.00, after a 3.01% drop. Over the past month, the stock decreased by 13.17%, and in the past year, by 27.40%. With performance like this, long-term shareholders are more likely to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2025/1744048849_0.png" alt="Past Year Chart" />

<h3>How Does Monolithic Power Systems P/E Compare to Other Companies?</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 99.88 in the Semiconductors &amp; Semiconductor Equipment industry, Monolithic Power Systems Inc. has a lower P/E ratio of 13.04. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1744048849_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

MPWR

P/E Ratio Insights for Monolithic Power Systems

In the latest quarter, 7 analysts provided ratings for OPKO Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>), showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $2.79, a high estimate of $3.00, and a low estimate of $2.25. This current average is unchanged from the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2025/1744048845_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive OPKO Health. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Yi Chen &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $3.00&#x7C;$3.00 &#x7C; 
&#x7C;Yi Chen &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $3.00&#x7C;$3.00 &#x7C; 
&#x7C;Yi Chen &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $3.00&#x7C;$3.00 &#x7C; 
&#x7C;Michael Petusky &#x7C;Barrington Research &#x7C;Maintains &#x7C;Outperform &#x7C; $2.25&#x7C;$2.25 &#x7C; 
&#x7C;Yi Chen &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $3.00&#x7C;$3.00 &#x7C; 
&#x7C;Michael Petusky &#x7C;Barrington Research &#x7C;Maintains &#x7C;Outperform &#x7C; $2.25&#x7C;$2.25 &#x7C; 
&#x7C;Yi Chen &#x7C;HC Wainwright &amp; Co. &#x7C;Maintains &#x7C;Buy &#x7C; $3.00&#x7C;$3.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to OPKO Health. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of OPKO Health compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of OPKO Health's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of OPKO Health's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/OPK/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on OPKO Health analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering OPKO Health: A Closer Look</h2>
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
<h3>Unraveling the Financial Story of OPKO Health</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining OPKO Health's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 0.95% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: OPKO Health's net margin excels beyond industry benchmarks, reaching 7.64%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 1.01%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): OPKO Health's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.63%, the company may face hurdles in achieving optimal financial returns.
Debt Management: OPKO Health's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.37.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

OPKO Health Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)

Throughout the last three months, 5 analysts have evaluated Cousins Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CUZ#NYSE">CUZ</a>), offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $34.0, a high estimate of $36.00, and a low estimate of $31.00. Experiencing a 2.86% decline, the current average is now lower than the previous average price target of $35.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1744048836_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of Cousins Props by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Andrew Rosivach &#x7C;Wolfe Research &#x7C;Announces &#x7C;Outperform &#x7C; $31.00&#x7C;- &#x7C; 
&#x7C;Peter Abramowitz &#x7C;Jefferies &#x7C;Announces &#x7C;Buy &#x7C; $35.00&#x7C;- &#x7C; 
&#x7C;David Rodgers &#x7C;Baird &#x7C;Lowers &#x7C;Outperform &#x7C; $33.00&#x7C;$34.00 &#x7C; 
&#x7C;Anthony Powell &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $35.00&#x7C;$36.00 &#x7C; 
&#x7C;Anthony Powell &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $36.00&#x7C;$35.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Cousins Props. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Cousins Props compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Cousins Props's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of Cousins Props's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CUZ/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Cousins Props analyst ratings.</a>
<h2>Delving into Cousins Props's Background</h2>
Cousins Properties Inc is a real estate investment trust principally involved in the ownership, management, and development of properties in the Southern United States. Cousins Properties' real estate portfolio mainly comprises offices and mixed-use developments that encompass both apartment and retail space. Offices make up the vast majority of the portfolio in terms of total square footage. The segments operates in following geographical areas: Atlanta, Austin, Charlotte, Dallas, Phoenix, Tampa, and other markets. The company derives nearly all of its revenue in the form of rental income from its properties, the majority of which comes from its office locations. A diverse set of tenants in the cities of Houston and Atlanta represent the company's key markets.
<h3>Cousins Props's Financial Performance</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Positive Revenue Trend: Examining Cousins Props's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 14.39% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Real Estate sector.
Net Margin: Cousins Props's net margin excels beyond industry benchmarks, reaching 6.05%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 0.29%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.16%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.65.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Cousins Props Through 5 Analysts

Snowflake's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) short percent of float has risen 5.57% since its last report. The company recently reported that it has 11.03 million shares sold short, which is 3.41% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.46 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Snowflake Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744048831_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Snowflake has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Snowflake's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Snowflake's peer group average for short interest as a percentage of float is 7.87%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

SNOW

Looking Into Snowflake's Recent Short Interest

LPL Finl Hldgs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPLA#NYSE">LPLA</a>) short percent of float has fallen 9.2% since its last report. The company recently reported that it has 1.09 million shares sold short, which is 1.48% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>LPL Finl Hldgs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744048826_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for LPL Finl Hldgs has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing LPL Finl Hldgs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, LPL Finl Hldgs's peer group average for short interest as a percentage of float is 3.39%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

LPLA

How Do Investors Really Feel About LPL Finl Hldgs?

Across the recent three months, 10 analysts have shared their insights on Semtech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Semtech, revealing an average target of $59.0, a high estimate of $85.00, and a low estimate of $30.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 16.45%. 
<img src="https://www.benzinga.com/files/images/story/2025/1744048823_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of Semtech by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Joseph Moore &#x7C;Morgan Stanley &#x7C;Announces &#x7C;Equal-Weight &#x7C; $30.00&#x7C;- &#x7C; 
&#x7C;Timothy Arcuri &#x7C;UBS &#x7C;Lowers &#x7C;Buy &#x7C; $60.00&#x7C;$65.00 &#x7C; 
&#x7C;Tore Svanberg &#x7C;Stifel &#x7C;Lowers &#x7C;Buy &#x7C; $54.00&#x7C;$60.00 &#x7C; 
&#x7C;Cody Acree &#x7C;Benchmark &#x7C;Lowers &#x7C;Buy &#x7C; $68.00&#x7C;$82.00 &#x7C; 
&#x7C;Quinn Bolton &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $54.00&#x7C;$54.00 &#x7C; 
&#x7C;Tore Svanberg &#x7C;Stifel &#x7C;Lowers &#x7C;Buy &#x7C; $70.00&#x7C;$75.00 &#x7C; 
&#x7C;Harsh Kumar &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Overweight &#x7C; $55.00&#x7C;$75.00 &#x7C; 
&#x7C;Quinn Bolton &#x7C;Needham &#x7C;Lowers &#x7C;Buy &#x7C; $54.00&#x7C;$74.00 &#x7C; 
&#x7C;Craig Ellis &#x7C;Baird &#x7C;Lowers &#x7C;Outperform &#x7C; $60.00&#x7C;$80.00 &#x7C; 
&#x7C;Timothy Arcuri &#x7C;UBS &#x7C;Announces &#x7C;Buy &#x7C; $85.00&#x7C;- &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Semtech. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Semtech compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Semtech's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Semtech's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/SMTC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Semtech analyst ratings.</a>
<h2>Get to Know Semtech Better</h2>
Semtech Corp is engaged in designing, developing, manufacturing and marketing analog and mixed-signal semiconductors, algorithms and wireless semiconductors, connectivity modules, gateways, routers and connected services for IoT. The company operates in four reportable segments: Signal Integrity, Analog Mixed Signal and Wireless, IoT Systems and IoT Connected Services. The majority of the company's revenue is earned through Analog Mixed Signal and Wireless segment. Geographically majority of the company's revenue is earned from Asia Pacific region, company also operates in North America and Europe.
<h3>Financial Insights: Semtech</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Semtech's remarkable performance in 3M is evident. As of 31 January, 2025, the company achieved an impressive revenue growth rate of 30.09%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: Semtech's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 15.6% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 19.44%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.8%, the company showcases effective utilization of assets.
Debt Management: Semtech's debt-to-equity ratio surpasses industry norms, standing at 1.03. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SMTC

Where Semtech Stands With Analysts

Costco Wholesale's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COST#NYSE">COST</a>) short percent of float has fallen 3.12% since its last report. The company recently reported that it has 6.87 million shares sold short, which is 1.55% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.19 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Costco Wholesale Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744048820_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Costco Wholesale has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Costco Wholesale's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Costco Wholesale's peer group average for short interest as a percentage of float is 4.88%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

COST

What Does the Market Think About Costco Wholesale?

In the preceding three months, 14 analysts have released ratings for Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">8</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $135.86, along with a high estimate of $247.00 and a low estimate of $85.00. Experiencing a 14.17% decline, the current average is now lower than the previous average price target of $158.29. 
<img src="https://www.benzinga.com/files/images/story/2025/1744048815_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Illumina among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Patrick Donnelly &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $85.00&#x7C;$90.00 &#x7C; 
&#x7C;Conor McNamara &#x7C;RBC Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $128.00&#x7C;$247.00 &#x7C; 
&#x7C;Mason Carrico &#x7C;Stephens &amp; Co. &#x7C;Maintains &#x7C;Overweight &#x7C; $156.00&#x7C;$156.00 &#x7C; 
&#x7C;Kyle Mikson &#x7C;Canaccord Genuity &#x7C;Lowers &#x7C;Hold &#x7C; $115.00&#x7C;$135.00 &#x7C; 
&#x7C;Catherine Ramsey &#x7C;Baird &#x7C;Lowers &#x7C;Neutral &#x7C; $90.00&#x7C;$127.00 &#x7C; 
&#x7C;Patrick Donnelly &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $90.00&#x7C;$130.00 &#x7C; 
&#x7C;Tejas Savant &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $136.00&#x7C;$150.00 &#x7C; 
&#x7C;David Westenberg &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $190.00&#x7C;$185.00 &#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Lowers &#x7C;Underweight &#x7C; $100.00&#x7C;$130.00 &#x7C; 
&#x7C;Conor McNamara &#x7C;RBC Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $247.00&#x7C;$250.00 &#x7C; 
&#x7C;Kyle Mikson &#x7C;Canaccord Genuity &#x7C;Lowers &#x7C;Hold &#x7C; $135.00&#x7C;$145.00 &#x7C; 
&#x7C;Subbu Nambi &#x7C;Guggenheim &#x7C;Lowers &#x7C;Buy &#x7C; $150.00&#x7C;$170.00 &#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $130.00&#x7C;$145.00 &#x7C; 
&#x7C;Tejas Savant &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $150.00&#x7C;$156.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Illumina. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Illumina compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Illumina's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Illumina's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ILMN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Illumina analyst ratings.</a>
<h2>Get to Know Illumina Better</h2>
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
<h3>A Deep Dive into Illumina's Financials</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Illumina's financials over 3M reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -1.6% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Illumina's net margin is impressive, surpassing industry averages. With a net margin of 16.94%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Illumina's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 8.31%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Illumina's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.04% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Illumina's debt-to-equity ratio is below the industry average at 1.1, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ILMN

Deep Dive Into Illumina Stock: Analyst Perspectives (14 Ratings)

Zhibao Technology Shares Halted On Circuit Breaker To The Upside, Stock Now Up 103.2%

At last check Monday, Janover Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JNVR#NASDAQ">JNVR</a>) shares were up over 560%. 
A team of former Kraken executives has taken majority ownership of the company to help bridge the gap between so-called traditional finance (TradFi) <a href="https://www.benzinga.com/pressreleases/25/04/g44664262/crypto-industry-leaders-acquire-majority-ownership-of-janover-inc" target="_blank" rel="noreferrer noopener">and decentralized finance (DeFi)</a>.
The control group acquired 728,632 common shares and all 10,000 Series A Preferred shares.
Joseph Onorati has been named Chairman and CEO, and Parker White will serve as Chief Investment and Operating Officer.
Janover&#8217;s Board has implemented a new treasury policy to allocate its principal reserves into digital assets, beginning with Solana (SOL).
The company plans to acquire and stake SOL by purchasing Solana validators—key nodes that validate transactions and uphold network consensus.
These validators earn SOL rewards. Janover aims to use the generated revenue to acquire more SOL, creating a self-sustaining cycle.
Staking on Solana is a multi-billion dollar industry, and this move positions Janover to capitalize on it while continuing its shift toward a SaaS business model.
Founder Blake Janover and CFO Bruce Rosenbloom will remain actively involved in ensuring operational continuity and service quality.
As part of the transaction, the company plans to change its name and ticker symbol in the near future.
The new name will be DeFi Development Corporation, reflecting its strategic shift toward decentralized finance initiatives.
The company also disclosed that it had raised around $42 million in an offering of convertible notes and<a href="https://www.benzinga.com/pressreleases/25/04/g44664273/new-janover-management-team-raises-approximately-42-million-to-enhance-u-s-public-market-digital-a" target="_blank" rel="noreferrer noopener"> warrants from several investors</a>. Proceeds will go toward acquiring digital assets, beginning with investments in the Solana ecosystem via U.S. public markets.
The notes, sold through a private offering, have a 2.5% annual interest rate, to be paid quarterly in cash.
The notes, expected to mature on April 6, 2030, can be converted into common stock if the company&#8217;s market cap hits $100 million on the day prior to the conversion date.
The conversion price will be the stock's last Nasdaq sale price at that time, with a minimum of $4.81.
For every $1,000 of notes, investors also receive warrants to buy ~8.3 shares at $120 and ~6.7 shares at $150, with standard anti-dilution protections.
Last month, the company reported fourth-quarter revenue growth of 80% year-on-year to $630,000. It also reported a net loss decline <a href="https://www.benzinga.com/news/earnings/25/03/44300683/exclusive-janover-clocks-80-q4-revenue-growth-488-surge-in-subscription-revenue">of 59% to $490,000</a>. 
Price Action: JNVR shares are up 555.75% at $26.23 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/04/44665396/shell-updates-q1-outlook-tightens-production-ranges-flags-write-offs-and-maintenance" target="_blank" rel="noreferrer noopener">Shell Lowers Q1 Production Outlook, Flags Write-Offs And Maintenance</a></li>
</ul>
Image: Shutterstock

Equities

Financing

Small Cap

Movers

JNVR

Why Are Janover Shares Rocketing On Monday?

Macro Economic Events

Politics

Global

Economics

General

EU Commission Proposes Counter-Tariffs On Some U.S. Imports To Take Effect From December 1

EU Commission Proposes Counter-Tariffs On Range Of U.S. Imports At 25% In Response To U.S. Steel Duties; Proposes 25% Tariff On U.S. Goods To Take Effect From May 16; Removes U.S. Bourbon From Its List Of Goods To Face Counter-Tariffs

Scotiabank analyst Mario Saric maintains Brookfield (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BN#NYSE">BN</a>) with a Sector Outperform and lowers the price target from $71 to $68.

Scotiabank Maintains Sector Outperform on Brookfield, Lowers Price Target to $68

Health Care

Press Releases

Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones

Tenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative Medicine

Tenaya Therapeutics to Participate in Upcoming March Investor Conferences

Tenaya Therapeutics Announces Proposed Public Offering

Tenaya Therapeutics Announces Pricing of Public Offering

Earnings

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology's Annual Scientific Session

Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models

Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting

Comments

Tenaya Therapeutics

空売り

Tenaya Therapeutics (NASDAQ:TNYA) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル